Online citations, reference lists, and bibliographies.

Pharmaco-Nutritional Supports For The Treatment Of Cancer Cachexia

M. Dahele, K. C. Fearon
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Cancer cachexia is a major symptom burden for patients with cancer.Cachexia occurs in up to one half of all patients diagnosed with cancer [1] and is more frequent in patients with lung and upper-gastrointestinal cancer.Cancer cachexia results from the interaction of the host and the tumour. However, the nature of this interaction is incompletely understood [2] [5], including the dynamics of the host response (activation of the systemic inflammatory response, metabolic, immune and neuroendocrine changes) and those tumour characteristics or tumour-derived products that influence expression of the syndrome (e.g. proteolysis-inducing factor [PIF]). The relative importance of individual mediators and pathways in different patients or tumour types is unclear, as is the reason why individuals with apparently similar tumours should show considerable variation in their tendency to develop cachexia.As ability to discriminate the relative importance in vivo of different mediators improves, so too should the ability to develop appropriately targeted therapy.
This paper references
10.1177/1534735404264736
Role of Omega-3 Fatty Acid Supplementation in Inflammation and Malignancy
D. Jho (2004)
10.1001/archotol.1982.00790590019006
Energy and tissue metabolism in patients with cancer during nutritional support.
S. Edström (1982)
10.1097/00005768-200205001-01398
CONCURRENT STRENGTH AND ENDURANCE TRAINING IN OLDER MEN
M. Izquierdo (2002)
10.1097/00000421-199808000-00006
Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia.
C. Vadell (1998)
10.1007/s005200100281
Is there a role for melatonin in supportive care?
P. Lissoni (2002)
10.1079/PNS2002166
Dietary modification of inflammation with lipids.
P. Calder (2002)
10.1097/00005768-200203000-00023
Creatine supplementation improves muscular performance in older men.
L. Gotshalk (2002)
10.1023/A:1011156811739
High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials.
M. Maltoni (2001)
10.1016/J.JNUTBIO.2004.02.002
Fish oil supplementation in F1 generation associated with naproxen, clenbuterol, and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing rats.
J. A. Pinto (2004)
10.1016/S0039-6060(96)80074-2
Depletion of high energy phosphate compouds in the tumor-bearing state and reversal after tumor resection.
S. Hochwald (1996)
10.1007/s00520-003-0530-0
Oral morphine and respiratory function amongst hospice inpatients with advanced cancer
T. D. Walsh (2003)
10.1016/S0889-8588(02)00011-4
Update on anorexia and cachexia.
F. Strasser (2002)
10.1136/gut.52.10.1479
Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial
K. Fearon (2003)
10.1023/A:1008291825695
Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial
E. Beller (1997)
10.1177/109980040100200301
Resistance Exercise Training Attenuates Wasting of the Extensor Digitorum Longus Muscle in Mice Bearing the Colon-26 Adenocarcinoma
S. Al-Majid (2001)
10.1097/00001813-200009000-00011
No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone
H. Fiebig (2000)
Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.
C. Cahlin (2000)
10.1002/NUR.20019
Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma.
D. McCarthy (2004)
10.1097/00005768-200003000-00024
American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation.
R. Terjung (2000)
10.1200/JCO.1995.13.11.2856
Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.
R. Goldberg (1995)
10.1016/S0304-3835(03)00472-5
Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats.
P. M. Piffar (2003)
10.1159/000224161
Physical function in men and women with cancer. Effects of anemia and conditioning.
W. Evans (2002)
10.1586/14737140.2.1.121
Anticancer drugs that induce cancer-associated cachectic syndromes
Akiko Tohgo (2002)
10.1002/BJS.1800820233
Effect of ibuprofen on the acute‐phase response and protein metabolism in patients with cancer and weight loss
T. Preston (1995)
10.1111/j.1365-2265.1978.tb02216.x
EFFECTS OF ORAL TESTOSTERONE UNDECANOATE IN HYPOGONADAL MALE PATIENTS *
P. Franchimont (1978)
10.1207/S15327914NC3602_6
Effect of Oral Eicosapentaenoic Acid on Weight Loss in Patients With Pancreatic Cancer
S. Wigmore (2000)
10.1200/JCO.1996.14.1.135
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
K. Rowland (1996)
10.1200/JCO.1994.12.6.1121
Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer.
C. L. Loprinzi (1994)
10.1038/sj.bjc.6601620
Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids
A. G. Moses (2004)
10.1200/JCO.1987.5.1.113
A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer.
W. Evans (1987)
Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS.
E. Engelson (1995)
10.1016/S0093-7754(02)70177-2
Epoetin alfa for protection of metabolic and exercise capacity in cancer patients.
P. Daneryd (2002)
10.1200/JCO.1999.17.10.3299
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
C. Loprinzi (1999)
10.1016/S0039-6060(05)80199-0
Effect of growth hormone and protein intake on tumor growth and host cachexia.
D. Bartlett (1995)
10.1007/s00520-002-0340-9
Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients
K. Nelson (2002)
10.1038/sj.bjc.6601560
Potential health risks of complementary alternative medicines in cancer patients
U. Werneke (2004)
10.1016/S0003-4975(01)02847-8
Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?
A. Jatoi (2001)
10.1177/030089168707300410
Impact of Hospitalization on the Nutritional Status of Cancer Patients
E. Ravera (1987)
10.1016/J.JPAINSYMMAN.2003.09.007
Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome.
A. Pascual López (2004)
10.1161/01.CIR.0000124490.27666.B2
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
D. Mann (2004)
10.1007/s005200050140
Parenteral versus enteral nutrition in cancer patients: indications and practice
S. Mercadante (1998)
10.1093/ajcn/34.10.1997
Body composition and dietary intake in neoplastic disease.
S. Cohn (1981)
10.1016/S0002-8223(00)00373-4
Impact of declines in nutritional status on outcomes in adult patients hospitalized for more than 7 days.
C. Braunschweig (2000)
10.1016/0277-5379(89)90353-2
Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group.
G. R. della Cuna (1989)
10.1016/S0016-5085(83)80234-0
Metabolic response of whole body and peripheral tissues to enteral nutrition in weight-losing cancer and noncancer patients.
K. Bennegȧrd (1983)
10.1007/BF01121584
Sympathetic activation of brown-adipose-tissue thermogenesis in cachexia
S. L. Brooks (1981)
10.1207/S15327914NC4601_07
Cancer Cachexia and Tumor Growth Reduction in Walker 256 Tumor-Bearing Rats Supplemented With N-3 Polyunsaturated Fatty Acids for One Generation
V. Togni (2003)
10.1159/000073337
What We Have Learned about Cachexia in Gastrointestinal Cancer
J. A. Palesty (2003)
10.1042/CS0920215
Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6.
S. Wigmore (1997)
10.1016/0899-9007(95)00067-4
Definition of standardized nutritional assessment and interventional pathways in oncology.
F. Ottery (1996)
Clinical trials update in human immunodeficiency virus wasting.
N. Muurahainen (1998)
10.1016/J.NUT.2003.08.004
Effects of simvastatin administration in an experimental model of cancer cachexia.
M. Muscaritoli (2003)
10.1016/j.mad.2004.01.004
Effects of testosterone on body composition of the aging male
Shiyama Mudali (2004)
10.1159/000048556
Anti-Cachectic Effect of Clarithromycin for Patients with Unresectable Non-Small Cell Lung Cancer
M. Sakamoto (2001)
10.1200/JCO.1994.12.6.1126
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.
C. Loprinzi (1994)
Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis.
A. McGeer (1990)
Anti-inflammatory activity of macrolide antibiotics.
A. Ianaro (2000)
10.1006/CYTO.1995.1003
The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.
S. Siegel (1995)
The report to Congress on the appropriate federal role in assuring access by medical students, residents, and practicing physicians to adequate training in nutrition.
Davis Ch (1994)
10.1016/S0140-6736(02)08024-8
Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study
G. Onder (2002)
10.1038/sj.bjc.6690077
A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss
D. McMillan (1999)
Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors.
K. Lundholm (1994)
Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study.
P. Daneryd (1998)
10.1186/bcr724
Are herbal remedies and dietary supplements safe and effective for breast cancer patients?
Aedín Cassidy (2003)
10.1615/CRITREVONCOG.V9.I2.10
Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms.
G. Mantovani (1998)
10.1210/JCEM.84.10.6046
Inactivity amplifies the catabolic response of skeletal muscle to cortisol.
A. Ferrando (1999)
10.1590/S0100-879X2003001100017
A leucine-supplemented diet improved protein content of skeletal muscle in young tumor-bearing rats.
M. C. Gomes-Marcondes (2003)
10.1016/S0899-9007(01)00629-3
Glutamine supplementation in cancer patients.
S. Yoshida (2001)
10.1016/S1072-7515(03)00382-X
Understanding and managing cancer cachexia.
N. Macdonald (2003)
10.1177/0148607188012003229
Effect of total parenteral nutrition on whole body protein kinetics in cachectic patients with benign or malignant disease.
M. Jeevanandam (1988)
10.1016/0022-4804(90)90024-V
Protein intake and 5-fluorouracil toxicity in tumor-bearing animals.
M. Torosian (1990)
10.1046/j.1365-2036.2003.01457.x
Oesophageal cancer and cachexia: the effect of short‐term treatment with thalidomide on weight loss and lean body mass
Z. Khan (2003)
10.1517/13543784.12.7.1211
Thalidomide: a new anticancer drug?
M. Fanelli (2003)
10.1177/109980040100200304
Cancer-Induced Fatigue and Skeletal Muscle Wasting: The Role of Exercise
S. Al-Majid (2001)
10.1007/S11912-002-0020-4
Adenosine triphosphate for cancer cachexia
T. D. Walsh (2002)
10.1016/S0959-8049(98)00219-6
Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial.
F. de Conno (1998)
10.1200/JCO.2004.06.024
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.
A. Jatoi (2004)
Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.
E. Bruera (1998)
10.1016/0014-2999(94)90229-1
Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations.
H. McCarthy (1994)
10.1093/JN/128.8.1355
Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response.
T. Preston (1998)
10.1007/s11745-001-0726-4
Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia
M. Barber (2001)
10.1126/SCIENCE.1069525
Induction of Cachexia in Mice by Systemically Administered Myostatin
T. Zimmers (2002)
10.1016/S0899-9007(01)80001-0
Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia.
C. Langer (2001)
Anorexia/Cachexia in Patients with HIV: Lessons for the Oncologist
G. Coodley (1996)
10.1042/CS0860339
Tumour and host tissue responses to branched-chain amino acid supplementation of patients with cancer.
M. McNurlan (1994)
10.1042/cs0820413
Stimulation of human breast cancers by dietary L-arginine.
K. Park (1992)
10.1200/JCO.2003.01.101
Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study.
E. Bruera (2003)
10.1038/sj.bjc.6601132
Increased expression of the ubiquitin – proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB
A. S. Whitehouse (2003)
10.1016/0277-5379(90)90221-E
The in vitro and in vivo effects of human growth hormone administration on tumor growth of rats bearing a transplantable rat pituitary tumor (7315b).
A. Binnerts (1990)
10.2174/1389450043490505
The pharmacological treatment of cachexia.
J. Argilés (2004)
10.1016/S0360-3016(03)01137-4
Ongoing placebo-controlled study of oxandrolone in cancer-related weight loss
S. Tchekmedyian (2003)
10.1159/000239580
Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin.
K. Mikasa (1997)
10.3322/canjclin.52.2.72
Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management
A. Inui (2002)
10.1097/00075197-200205000-00002
Eicosanoid-dependent cancer cachexia and wasting
J. Ross (2002)
10.1016/S0959-8049(99)00159-8
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.
P. Lissoni (1999)
10.1177/014860719201600605
Hormonal and metabolic abnormalities in the malnourished cancer patient: effects on host-tumor interaction.
D. Heber (1992)
10.1093/jn/132.11.3508S
Omega-3 fatty acids to augment cancer therapy.
W. Hardman (2002)
10.1038/sj.bjc.6601981
Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice
H. J. Smith (2004)
Insulin reversal of cancer cachexia in rats.
J. Moley (1985)
10.1080/09629359990351
Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo.
H. Suzaki (1999)
10.1111/j.1365-2362.1993.tb00716.x
Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours
A. Hyltander (1993)
10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V
Corticosteroid therapy of preterminal gastrointestinal cancer
C. Moertel (1974)
10.3892/IJO.24.3.505
Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia.
K. Lundholm (2004)
10.1016/S0149-2918(05)80001-3
Prognostic effect of weight loss prior tochemotherapy in cancer patients
W. Dewys (1980)
Comparison of a malnutrition screening tool with subjective global assessment in hospitalised patients with cancer--sensitivity and specificity.
J. Bauer (2003)
10.1016/S1470-2045(03)01247-6
Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies.
A. Laviano (2003)
10.7326/0003-4819-121-6-199409150-00001
Megestrol Acetate in Patients with AIDS-related Cachexia
J. V. Von Roenn (1994)
10.1207/S15327914NC422_1
Exercise, Cachexia, and Cancer Therapy: A Molecular Rationale
C. Ardies (2002)
10.1097/00043426-200305000-00013
Mechanism of Transient Adrenal Insufficiency With Megestrol Acetate Treatment of Cachexia in Children With Cancer
L. Meacham (2003)
10.1016/S0006-2952(00)00578-5
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo.
Y. Eli (2001)
10.1093/CARCIN/BGG060
Erythropoietin regulates tumour growth of human malignancies.
Y. Yasuda (2003)
10.1159/000007256
Adjuvant Effect of Clarithromycin on Chemotherapy for Murine Lung Cancer
K. Hamada (1999)
10.1152/ajpendo.1999.277.2.E332
A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.
D. Lazarus (1999)
Hyperalimentation of the cancer patient with protein-calorie undernutrition.
D. Nixon (1981)
10.1002/1097-0142(19880501)61:9<1731::AID-CNCR2820610902>3.0.CO;2-A
Reduction of methotrexate toxicity with improved nutritional status in tumor‐bearing animals
M. Torosian (1988)
10.1002/1097-0142(197905)43:5+<2036::AID-CNCR2820430712>3.0.CO;2-7
Alterations of nutritional status. Impact of chemotherapy and radiation therapy
S. Donaldson (1979)
10.1177/014860710402800265
Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters.
J. Rathmacher (2004)
10.1007/s00520-002-0387-7
Established and potential therapeutic applications of cannabinoids in oncology
D. Walsh (2002)
10.1097/00001813-200203000-00003
Perindopril: possible use in cancer therapy
H. Yoshiji (2002)
10.1016/S0959-8049(03)00456-8
Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study.
D. Kotasek (2003)
10.1136/bmj.288.6410.27
Prednisolone as an appetite stimulant in patients with cancer.
J. Willox (1984)
10.1210/JCEM.87.5.8505
Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial.
C. Lambert (2002)
10.1016/S0885-3924(03)00043-5
Rapid progression of advanced "hormone-resistant" prostate cancer during palliative treatment with progestins for cancer cachexia.
D. Tassinari (2003)
10.1158/1078-0432.CCR-0629-3
Rapamycin Inhibits the Growth and Metastatic Progression of Non-Small Cell Lung Cancer
D. Boffa (2004)
10.1002/cncr.20160
Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function
K. Lundholm (2004)
Palliative treatment of cancer anorexia with oral suspension of megestrol acetate.
M. Tomíška (2003)
10.1200/JCO.20.2.567
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.
A. Jatoi (2002)
10.1177/0148607193017006513
Parenteral nutrition in cancer patients receiving chemotherapy: effects on toxicity and nutritional status.
M. De Cicco (1993)
10.1016/0277-5379(91)90051-E
Effect on whole-body protein synthesis after institution of intravenous nutrition in cancer and non-cancer patients who lose weight.
A. Hyltander (1991)
10.1016/S0002-9610(02)00823-1
Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine
P. E. May (2002)
10.1200/JCO.1993.11.10.2043
Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study.
L. Ovesen (1993)
10.1038/sj.bjc.6601090
Standards, Options and Recommendations for the use of appetite stimulants in oncology (2000)
J. Desport (2003)
10.1093/ajcn/48.1.144
Influence of stress, depletion, and/or malignant disease on the responsiveness of surgical patients to total parenteral nutrition.
J. H. Shaw (1988)
10.1002/cncr.11502
Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression
L. Orme (2003)
10.1002/1097-0215(20000701)87:1<95::AID-IJC14>3.0.CO;2-D
Effect of the specific cyclooxygenase‐2 inhibitor meloxicam on tumour growth and cachexia in a murine model
H. J. Hussey (2000)
10.1177/014860719902300606
Use of growth hormone and other anabolic agents in AIDS wasting.
K. Mulligan (1999)
10.1016/S0959-8049(99)00273-7
Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients.
A. Hyltander (2000)
10.1016/S0167-5273(02)00239-5
Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia.
M. Brink (2002)
10.1177/0148607102026005291
Eicosapentaenoic acid supplementation reduces tumor volume and attenuates cachexia in a rat model of progressive non-metastasizing malignancy.
D. Jho (2002)
10.1210/JCEM.86.11.7983
Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases.
S. Basaria (2001)
10.1046/j.1365-2265.2002.01540.x
What is the role of the insulin‐like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated?
A. Crown (2002)
10.1007/BF01150477
The effect of clenbuterol on body composition in spontaneously eating tumour-bearing mice
A. Hyltander (1993)
10.1038/bjc.1988.263
A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model.
M. Tisdale (1988)
10.1093/AJCN/77.4.764
Immunonutrition: problematic or problem solving?
K. McCowen (2003)
10.1097/00001813-200309000-00009
Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients
H. Agteresch (2003)
10.1097/00000658-199904000-00004
Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials.
S. Heys (1999)
10.5555/uri:pii:009377549090002K
Appetite stimulation and weight gain with megestrol acetate.
J. Aisner (1990)
10.1097/00005768-200202000-00023
Effects of creatine supplementation on muscle power, endurance, and sprint performance.
M. Izquierdo (2002)
10.1200/JCO.1994.12.6.1113
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.
M. Kosty (1994)
Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice.
S. Samuels (2000)
10.1139/H02-039
Dietary creatine supplementation and exercise performance: why inconsistent results?
P. Lemon (2002)
10.1038/nm1203-1439
Erythropoietin may impair, not improve, cancer survival
V. Brower (2003)
10.1016/J.JPAINSYMMAN.2003.05.010
Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.
L. Cerchietti (2004)
10.1002/1097-0142(19850101)55:1+<268::AID-CNCR2820551311>3.0.CO;2-2
Critical evaluation of the role of nutritional support with chemotherapy
R. Chlebowski (1985)
10.1152/AJPCELL.00088.2004
The COX-2 pathway is essential during early stages of skeletal muscle regeneration.
Brenda A Bondesen (2004)
Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin.
B. Ng (1993)
10.1200/JCO.1993.11.1.152
Body-composition changes in patients who gain weight while receiving megestrol acetate.
C. Loprinzi (1993)
10.1042/CS20030301
Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients.
M. Barber (2004)
10.1093/AJCN/76.2.454
The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production.
R. Grimble (2002)
10.1177/1099800403005001001
Rethinking Nutritional Support for Persons with Cancer Cachexia
D. McCarthy (2003)
10.1177/0148607100024003133
Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study.
R. Clark (2000)
Enteral versus parenteral nutritional support in cancer patients.
D. Lawson (1981)
10.1002/bjs.1800780430
Stimulation of protein synthesis in human tumours by parenteral nutrition: Evidence for modulation of tumour growth
S. Heys (1991)
10.1002/1097-0142(19940301)73:5<1499::AID-CNCR2820730529>3.0.CO;2-O
Growth hormone, insulin, and somatostatin therapy of cancer cachexia
D. Bartlett (1994)
10.1002/ijc.1332
Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients
I. Bosaeus (2001)
10.1002/1097-0142(19900615)65:12<2657::AID-CNCR2820651210>3.0.CO;2-S
A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia
Carl G. Kardinal (1990)
10.1038/sj.bjc.6600175
Consumption of an omega-3 fatty acids product, INCELL AAFA™, reduced side-effects of CPT-11 (irinotecan) in mice
W. Hardman (2002)
10.2165/00002512-200219020-00002
Thalidomide in Cancer Treatment
Shu-feng Zhou (2002)
10.1016/S0026-0495(99)90074-4
Intralipid infusion combined with propranolol administration has favorable metabolic effects in elderly malnourished cancer patients.
A. Gambardella (1999)
10.1515/JPEM.1993.6.1.93
Growth Hormone and Prostate Cancer Growth and Metastasis in Tumor-Bearing Animals
M. Torosian (1993)
10.1016/S0304-3835(97)04718-6
Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth.
N. Carbó (1997)
10.1080/09629350310001599620
Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice.
Hajime Terao (2003)
10.1016/S0167-5273(02)00470-9
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.
S. Anker (2002)
10.1007/BF02303705
Effect of glutamine on tumor and host growth
D. Bartlett (2006)
10.1124/JPET.103.063099
Inhibition of Cyclooxygenase-2 by Celecoxib Reverses Tumor-Induced Wasting
T. Davis (2004)
10.1136/BMJ.327.7407.117
Immunonutrition: May have beneficial effects in surgical patients
P. Calder (2003)
10.14670/HH-18.1243
Muscle injuries and repair: the role of prostaglandins and inflammation.
V. Prisk (2003)
10.1016/S0959-8049(99)00055-6
Effects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependency.
S. I. Helle (1999)



Semantic Scholar Logo Some data provided by SemanticScholar